France · Source-listed medicine information
France / CIS 60307630
SUPPLIVEN, solution à diluer pour perfusion
solution à diluer pour perfusion · intraveineuse
Source data retrieved: 2026-09-17. Clinical review is not yet available.
Product identity
At a glance
- Authorisation holder
- FRESENIUS KABI FRANCE
- Authorisation status
- Autorisation active
- Market status
- Commercialisée
- Country
- France
- Source reference
- CIS 60307630
Reported market status does not confirm current pharmacy stock.
From the official composition record
Ingredients & strength
Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.
| Ingredient | Strength / reference | Source role |
|---|---|---|
| IODURE DE POTASSIUMsolution | 166 microgrammesune ampoule de 10 mL | SAGroup 9 |
| CHLORURE DE ZINCsolution | 10,5 mgune ampoule de 10 mL | SAGroup 4 |
| MOLYBDATE DE SODIUM DIHYDRATÉsolution | 48,5 microgrammesune ampoule de 10 mL | SAGroup 1 |
| FLUORURE DE SODIUMsolution | 2,1 mgune ampoule de 10 mL | SAGroup 8 |
| CHLORURE DE CHROME HEXAHYDRATÉsolution | 53,3 microgrammesune ampoule de 10 mL | SAGroup 7 |
| CHLORURE DE MANGANÈSE TÉTRAHYDRATÉsolution | 198 microgrammesune ampoule de 10 mL | SAGroup 5 |
| SÉLÉNITE DE SODIUMsolution | 173 microgrammesune ampoule de 10 mL | SAGroup 2 |
| CHLORURE DE CUIVRE DIHYDRATÉsolution | 1,02 mgune ampoule de 10 mL | SAGroup 6 |
| CHLORURE FERRIQUE HEXAHYDRATÉsolution | 5,4 mgune ampoule de 10 mL | SAGroup 3 |
Pack references
Presentations (1)
CIP13 3400930013748
Présentation active · Déclaration de commercialisationFrom the French medicines authority
Official documents
The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.
Open the official product entryBDPM · CIS 60307630 · Opens in a new tabCheck the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.
Where this information comes from
Sources & dates
Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.
| Source file | Retrieved | Source file modified |
|---|---|---|
| fr_products.txt | Not supplied | |
| fr_composition.txt | Not supplied | |
| fr_packs.txt | Not supplied |
Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.
Our sources and review process →